semaglutide cas 1169630-82-3 (Semaglutide intermediate P29) Semaglutide Intermediate P29 | 1169630-82-3
Description
GLP-1 medications lower the chance of serious heart problems like heart attacks or strokes
Clinical trials have shown that people can lose up to 15-20% of their body weight
When the drug shortage ended, the FDA banned the sale of compounded semaglutide after May 2025
Its key ingredient, tirzepatide, targets both the hormone GLP-1 and another, called GIP
While these large-scale observational studies are encouraging, more research is needed, including randomized controlled trials to determine whether GLP-1 medications directly reduce substance use, including stimulant use, and improve long-term recovery outcomes
